Condition
HR-positive/HER2-negative advanced breast cancer
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Fulvestrant
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Not Yet Recruiting1
Clinical Trials (1)
Research Network
Common Treatments
- Fulvestrant1
- Zongertinib1
Active Sponsors
- Medica Scientia Innovation Research S.L.1
- MedSIR1
- Boehringer Ingelheim1
Top Investigators
Institute of Breast Cancer, Quirón Group, Barcelona (Spain)
Related Conditions
- Hormone Receptor Positive Her2negative Breast Cancer1
- Her2 Mutation1
- Advanced Breast Cancer1